+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology

Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology

Journal of Thoracic Oncology 3(4): 365-373

This prospective study examined association between circulating plasma DNA, microsatellite alterations (MA), p53 mutations with time to relapse and survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts). Plasma samples, adjacent lung tissue, and lung tumor tissue specimens were collected from consecutive patients with stage I-III NSCLC. Blood samples of 66 matched healthy donors with positive smoking history were collected as controls. The plasma DNA amount was determined by real-time PCR. The analysis of MA at loci D3S1300, D3S1289, D3S1266, and D3S2338 on chromosome 3p was performed by radiolabeled PCR. p53 Mutations (exons 5, 6, 7, and 8) were detected by PCR-single-strand conformational polymorphism assay. There were 76 patients, 65 men; median age was 68 years (range, 42-86), 20 had stage I, 40 stage II, and 16 stage III, the majority of pts (48.7%) had squamous-cell histology. Sixty-nine (91%) were smokers and most had good Eastern Cooperative Oncology Group performance status (0/1:72/4). Mean circulating DNA of all pts was 60 ng/ml versus 5 ng/ml in smoker-matched controls (p < 0.0001). In pts without recurrence, mean circulating DNA was 48.5 ng/ml at baseline, 32.8 ng/ml at 3 month, and 20.6 ng/ml at 12 month after surgery. In pts with recurrence, mean circulating DNA at baseline was 97.1 ng/ml. At 3 month after surgery, mean DNA concentration was significantly lower in disease-free pts than in patients with recurrent disease (32.8 versus 292.7 ng/ml; p = 0.0016). MA in at least one locus was found in 39.5% of NSCLC tumors. p53 Genomic mutations were observed in 54.0% of tumor samples. Statistically significant associations were observed between MA and squamous-cell histotype (p = 0.007) and between p53 mutations and lymph node involvement (p = 0.012). MA and p53 mutations were found to be significantly associated with recurrence of disease (p = 0.033 and 0.026, respectively). Our results suggest that MA and p53 mutations in tumor DNA have a potential prognostic role for disease recurrence in NSCLC patients, and elevated levels of plasma circulating DNA identify patients with possible systemic disease at diagnosis. This might be proposed as an early detection test of disease recurrence.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055018655

Download citation: RISBibTeXText

PMID: 18379354

DOI: 10.1097/jto.0b013e318168c7d0

Related references

O-112 Microsatellite alterations and P53 mutations in tumor and plasma DNA of resected non small cell lung cancer (NSCLC) patients. (A study of the Perugia Multidisciplinary team for thoracic tumors). Lung Cancer 49: S39-S40, 2005

Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. Tumori 94(3): 398-405, 2008

P-183 Post-operative thoracic radiation therapy (TRT) in radically resected, chemonaive IIIA N2 non-small cell lung cancer (NSCLC) patients: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 010). Lung Cancer 41: S136-S137, 2003

Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer. Lung Cancer 128: 152-157, 2019

Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. Oncoimmunology 6(11): E1360458, 2017

Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer. Annals of Thoracic Surgery 84(1): 182-8; Discussion 189-90, 2007

Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Annals of Oncology 11(9): 1097-1104, 2000

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. Oncotarget 8(15): 25189-25199, 2017

Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809. American Journal of Clinical Oncology 2018:, 2018

Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer. Anticancer Research 36(8): 4329-4336, 2016

Prognostic significance of tumor-infiltrating CD8⁺ or CD3⁺ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer. Chinese Medical Journal 128(1): 105-110, 2015

Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Medicine 2(9): 1033-1035, 1996

P0215 Effects of multidisciplinary team care on the survival of patients with non-small-cell lung cancer in Taiwan. European Journal of Cancer 50: e69-e70, 2014

Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients With Non-small-cell Lung Cancer. Clinical Lung Cancer 20(4): E430-E441, 2019

Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. Journal of Clinical Oncology 15(6): 2456-2466, 1997